Geode Capital Management
ANTX icon

Geode Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Geode Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38M Buy
697,806
+411,259
+144% +$1.77M ﹤0.01% 3064
2026
Q1 		$981K Buy
286,547
+34,672
+14% +$71.6K ﹤0.01% 3357
2025
Q4 		$287K Buy
251,875
+2,524
+1% +$2.95K ﹤0.01% 3791
2025
Q3 		$317K Hold
249,351
– – ﹤0.01% 3777
2025
Q2 		$264K Sell
249,351
-4,572
-2% -$5.45K ﹤0.01% 3779
2025
Q1 		$345K Buy
253,923
+26,127
+11% +$32.9K ﹤0.01% 3673
2024
Q4 		$314K Buy
227,796
+7,634
+3% +$9.26K ﹤0.01% 3747
2024
Q3 		$236K Buy
220,162
+39,239
+22% +$68.1K ﹤0.01% 3854
2024
Q2 		$389K Buy
180,923
+1,553
+0.9% +$3.7K ﹤0.01% 3664
2024
Q1 		$583K Buy
179,370
+747
+0.4% +$8.13K ﹤0.01% 3551
2023
Q4 		$3.66M Buy
178,623
+88,932
+99% +$1.49M ﹤0.01% 2857
2023
Q3 		$1.44M Buy
89,691
+36,729
+69% +$416K ﹤0.01% 3186
2023
Q2 		$450K Sell
52,962
-91,985
-63% -$661K ﹤0.01% 3684
2023
Q1 		$1.43M Buy
144,947
+21,862
+18% +$243K ﹤0.01% 3174
2022
Q4 		$1.17M Buy
123,085
+39,794
+48% +$533K ﹤0.01% 3279
2022
Q3 		$1.45M Buy
83,291
+6,824
+9% +$79.6K ﹤0.01% 3210
2022
Q2 		$592K Buy
+76,467
New +$1.01M ﹤0.01% 3672

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Geode Capital Management's ANTX Position: Q2 2026 in Review

Geode Capital Management increased its AN2 Therapeutics (ANTX) stake by 144% in Q2 2026, buying an estimated $1.77M and bringing the position to 697,806 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

Geode Capital Management first reported a position in ANTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $3.66M in Q4 2023. 57 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Geode Capital Management held 697,806 shares of AN2 Therapeutics worth $3.38M as of Q2 2026.
  • Geode Capital Management bought 411,259 AN2 Therapeutics shares in Q2 2026, an estimated $1.77M.
  • AN2 Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3064 holding.
  • Geode Capital Management first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Geode Capital Management's AN2 Therapeutics position peaked at $3.66M in Q4 2023.
  • 57 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.